New trial aims to wipe out hidden leukemia before transplant
NCT ID NCT05554419
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 38 times
Summary
This Phase 2 trial tests whether combining different chemotherapy drugs can better eliminate residual leukemia cells in patients with acute myeloid leukemia (AML) before they receive a stem cell transplant. About 184 adults aged 18-59 will be assigned to one of four treatment arms, including standard cytarabine alone or combinations with venetoclax, liposomal daunorubicin-cytarabine, or azacitidine. The goal is to see if these combinations lead to a deeper remission (no detectable disease) compared to standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cytarabine, venetoclax, liposome-encapsulated daunorubicin-cytarabine, azacitidine
What this could lead to
If successful, this could point toward more effective ways to eliminate remaining leukemia cells before transplant, potentially improving long-term survival.
What could go wrong
This is an early Phase 2 trial with a small number of participants. The drug combinations may not work better than standard treatment, and side effects like infection or organ damage are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.